<DOC>
	<DOCNO>NCT01949194</DOCNO>
	<brief_summary>In recent year , anti-angiogenic agent incorporated clinical practice treatment metastatic CRC , lead improvement progression-free survival overall survival . Regorafenib oral multi-kinase inhibitor target angiogenic oncogenic kinase . Although structurally similar another multi-kinase inhibitor , sorafenib , appear pharmacologically potent posse broader antiangiogenic property . Both sorafenib regorafenib target BRAF wild-type BRAF V600E mutant inhibition p38 MAP kinase peculiar characteristic regorafenib . A Phase I study regorafenib single agent patient heavily pretreated CRC show promising clinical activity disease control rate ( PR + SD ) 59 % evaluable patient . In Phase III trial ( CORRECT ) , randomize double-blind , placebo-controlled study compare either regorafenib plus best supportive care ( BSC ) placebo plus BSC , show regorafenib significantly increase overall survival ( OS ) , progression-free survival ( PFS ) disease control rate ( DCR ) , independently KRAS status . A major interest , give data present CORRECT trial , determine predictive biomarkers indicate patient likely benefit , resistant anti-angiogenic compound . This study aim determine efficacy regorafenib single-agent treatment treatment second-line metastatic colorectal cancer identify predictive biomarkers actual metastatic tumor treat . In case metastatic CRC patient , liver lesion frequently common site metastatic deposit lesion biopsied assess putative biomarkers . Patients ask undergo biopsy metastatic lesion prior treatment , optional liver biopsy time relapse . Using several high-throughput discovery platform , biomarkers identify metastatic tumor specimen blood sample collect throughout treatment . This allow u evaluate putative biomarkers monitor tumor biomarker dynamic use serial blood collection . The objective trial help identify patient subgroup likely responsive resistant regorafenib , future treatment regorafenib direct responsive yet identify patient population .</brief_summary>
	<brief_title>Study Determine Efficacy Regorafenib Metastatic Colorectal Cancer Patients Discover Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent . 2 . Age ≥18 year . 3 . Histological documentation adenocarcinoma colon rectum , least one liver metastatic site available biopsy . 4 . Metastatic disease suitable upfront curativeintent surgery . 5 . Patients must receive one ( one ) prior treatment regimen metastatic CRC . 6 . Measurable disease accord RECIST v.1.1 . 7 . ECOG status ≤1 . 8 . Life expectancy ≥ 3 month . 9 . Women childbearing potential men must agree use adequate contraception since signing inform consent form least 3 month last study drug administration . 10 . Adequate bonemarrow , liver , renal function : Total bilirubin ≤1.5 × ULN ALT AST ≤5 × ULN ( since liver involvement cancer ) Alkaline phosphatase limit ≤5 × ULN , since liver involvement cancer Amylase lipase ≤1.5 × ULN Serum creatinine ≤1.5 × ULN INR PTT ≤1.5 × ULN . Platelet count ≥100 x 10^9/L , hemoglobin ≥90 g/L , absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L 1 . Previous treatment regorafenib . 2 . Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year randomization , EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer superficial bladder tumour . 3 . Extended field radiotherapy within 4 week limited field radiotherapy within 2 week prior registration . Patients must recover therapyrelated toxicity . The site irradiation evidence progressive disease ( new lesion increase lesion size ) site disease . 4 . Major surgical procedure significant traumatic injury within 28 day start study treatment . 5 . Female patient pregnant breastfeeding . 6 . Congestive heart failure ≥ Class 2 accord NYHA . 7 . Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start study drug 8 . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) . 9 . Uncontrolled hypertension 10 . Phaeochromocytoma 11 . Pleural effusion ascites cause respiratory compromise . 12 . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 3 month start study treatment . 13 . Ongoing uncontrolled infection &gt; Grade 2 per CTCAE v. 4.0 . 14 . Known history HIV infection . 15 . Active hepatitis B C , chronic hepatitis B C require antiviral therapy . 16 . Seizure disorder require medication . 17 . Any history currently know brain metastasis ( patient stable brain metastasis ≥ 3 month may eligible study ) . 18 . History organ allograft . 19 . Evidence history severe bleed diathesis . 20 . Nonhealing wound , ulcer , bone fracture . 21 . Renal failure require haemodialysis peritoneal dialysis 22 . Dehydration ≥ 2 per CTCAE v. 4.0 . 23 . Substance abuse medical , psychological , social condition may interfere patient 's participation study evaluation study result . 24 . Known hypersensitivity regorafenib , regorafenib class drug , excipients formulation . 25 . Any illness medical condition unstable could jeopardize safety patient opinion investigator . 26 . Interstitial lung disease ongoing sign symptoms time informed consent . 27 . Persistent proteinuria ≥ Grade 3 per CTCAE v. 4.0 ( i.e . &gt; 3.5g/24 hour ) . 28 . Inability swallow oral medication . 29 . Any malabsorption condition . 30 . Unresolved toxicity &gt; Grade 1 , attribute prior therapy/procedure , exclude alopecia oxaliplatin neurotoxicity ≤ Grade 2 , per CTCAE v. 4.0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>liver metastasis</keyword>
</DOC>